Evidence map›Paper›PMID 23238815›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2013

Part I. Molecular and cellular characterization of high nitric oxide-adapted human breast adenocarcinoma cell lines.

B J Vesper, A Onul, G K Haines, G Tarjan, J Xue, K M Elseth, B Aydogan, M B Altman, J C Roeske, W A Paradise and 2 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Glutamine at focus: versatile roles in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
  2. Article
  3. A549 cells adapted to high nitric oxide show reduced surface CEACAM expression and altered adhesion and migration properties.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  4. Part II-mechanism of adaptation: A549 cells adapt to high concentration of nitric oxide through bypass of cell cycle checkpoints.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  5. Part I-mechanism of adaptation: high nitric oxide adapted A549 cells show enhanced DNA damage response and activation of antiapoptotic pathways.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  6. Article
  7. Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

B J VesperCenter for Molecular Biology of Oral Diseases, University of Illinois at Chicago, College of Dentistry, 801 S. Paulina Street, Chicago, IL 60612, USA.
A Onul
G K Haines
G Tarjan
J Xue
K M Elseth
B Aydogan
M B Altman
J C Roeske
W A Paradise
H De Vitto
J A Radosevich
University of Illinois Chicago · USUniversity of Chicago · USJohn H. Stroger, Jr. Hospital of Cook County · USLoyola University Medical Center · USUniversidade Federal do Rio de Janeiro · BRYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a lack of understanding of the casual mechanisms behind the observation that some breast adenocarcinomas have identical morphology and comparatively different cellular growth behavior. This is exemplified by a differential response to radiation, chemotherapy, and other biological intervention therapies. Elevated concentrations of the free radical nitric oxide (NO), coupled with the up-regulated enzyme nitric oxide synthase (NOS) which produces NO, are activities which impact tumor growth. Previously, we adapted four human breast cancer cell lines: BT-20, Hs578T, T-47D, and MCF-7 to elevated concentrations of nitric oxide (or high NO [HNO]). This was accomplished by exposing the cell lines to increasing levels of an NO donor over time. Significantly, the HNO cell lines grew faster than did each respective ("PARENT") cell line even in the absence of NO donor-supplemented media. This was evident despite each "parent" being morphologically equivalent to the HNO adapted cell line. Herein, we characterize the HNO cells and their biological attributes against those of the parent cells. Pairs of HNO/parent cell lines were then analyzed using a number of key cellular activity criteria including: cell cycle distribution, DNA ploidy, response to DNA damage, UV radiation response, X-ray radiation response, and the expression of significant cellular enzymes. Other key enzyme activities studied were NOS, p53, and glutathione S-transferase-pi (GST-pi) expression. HNO cells were typified by a far more aggressive pattern of growth and resistance to various treatments than the corresponding parent cells. This was evidenced by a higher S-phase percentage, variable radioresistance, and up-regulated GST-pi and p53. Taken collectively, this data provides evidence that cancer cells subjected to HNO concentrations become resistant to free radicals such as NO via up-regulated cellular defense mechanisms, including p53 and GST-pi. The adaptation to NO may explain how tumor cells acquire a more aggressive tumor phenotype.

Indexed as

Adaptation, PhysiologicalAdenocarcinomaBreast NeoplasmsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGlutathione S-Transferase piHumansNitric OxideNitric Oxide DonorsNitric Oxide SynthaseTumor Suppressor Protein p53Up-RegulationGlutathione S-Transferase piNitric OxideNitric Oxide DonorsNitric Oxide SynthaseTumor Suppressor Protein p53

Identifiers

PMID23238815
OpenAlexW2080859821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.